Eribulin mesylate in the treatment of metastatic breast cancer

Sarika Jain, Tessa CiglerDepartment of Medicine, Weill Cornell Medical College, New York, NY, USAAbstract: The treatment of metastatic breast cancer (MBC) has become increasingly challenging as the primary goals of therapy include prolonging life without added toxicity. While multiple agents are app...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jain S, Cigler T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/e4b6daa81e6f4cc294aa1d0945c94463
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e4b6daa81e6f4cc294aa1d0945c94463
record_format	dspace
spelling	oai:doaj.org-article:e4b6daa81e6f4cc294aa1d0945c944632021-12-02T04:39:28ZEribulin mesylate in the treatment of metastatic breast cancer1177-54751177-5491https://doaj.org/article/e4b6daa81e6f4cc294aa1d0945c944632012-01-01T00:00:00Zhttp://www.dovepress.com/eribulin-mesylate-in-the-treatment-of-metastatic-breast-cancer-a9034https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Sarika Jain, Tessa CiglerDepartment of Medicine, Weill Cornell Medical College, New York, NY, USAAbstract: The treatment of metastatic breast cancer (MBC) has become increasingly challenging as the primary goals of therapy include prolonging life without added toxicity. While multiple agents are approved for the therapy of MBC, there is no standard approach for therapy beyond the second-line. Eribulin mesylate, an analog of the marine sponge halichondrin B, is a non-taxane microtubule dynamics inhibitor with a mechanism of action distinct from other tubulin-targeted drugs. Based on a significant extension in overall survival seen in a Phase III clinical trial, eribulin was approved for third-line therapy in MBC patients following anthracycline and taxane failure. Eribulin has a manageable toxicity profile and a low incidence of peripheral neuropathy. In this review, we discuss the natural source of eribulin, pharmacology, mode of action, preclinical and clinical data, and patient-focused perspectives.Keywords: eribulin, metastatic breast cancer, microtubuleJain SCigler TDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 21-29 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Jain S Cigler T Eribulin mesylate in the treatment of metastatic breast cancer
description	Sarika Jain, Tessa CiglerDepartment of Medicine, Weill Cornell Medical College, New York, NY, USAAbstract: The treatment of metastatic breast cancer (MBC) has become increasingly challenging as the primary goals of therapy include prolonging life without added toxicity. While multiple agents are approved for the therapy of MBC, there is no standard approach for therapy beyond the second-line. Eribulin mesylate, an analog of the marine sponge halichondrin B, is a non-taxane microtubule dynamics inhibitor with a mechanism of action distinct from other tubulin-targeted drugs. Based on a significant extension in overall survival seen in a Phase III clinical trial, eribulin was approved for third-line therapy in MBC patients following anthracycline and taxane failure. Eribulin has a manageable toxicity profile and a low incidence of peripheral neuropathy. In this review, we discuss the natural source of eribulin, pharmacology, mode of action, preclinical and clinical data, and patient-focused perspectives.Keywords: eribulin, metastatic breast cancer, microtubule
format	article
author	Jain S Cigler T
author_facet	Jain S Cigler T
author_sort	Jain S
title	Eribulin mesylate in the treatment of metastatic breast cancer
title_short	Eribulin mesylate in the treatment of metastatic breast cancer
title_full	Eribulin mesylate in the treatment of metastatic breast cancer
title_fullStr	Eribulin mesylate in the treatment of metastatic breast cancer
title_full_unstemmed	Eribulin mesylate in the treatment of metastatic breast cancer
title_sort	eribulin mesylate in the treatment of metastatic breast cancer
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/e4b6daa81e6f4cc294aa1d0945c94463
work_keys_str_mv	AT jains eribulinmesylateinthetreatmentofmetastaticbreastcancer AT ciglert eribulinmesylateinthetreatmentofmetastaticbreastcancer
_version_	1718401157971312640

Eribulin mesylate in the treatment of metastatic breast cancer

Ejemplares similares